Horizon nabs another rare disease pipeline for the portfolio in $3B buyout. And AstraZeneca — a future rival — is getting about $780M of that

Seven months after scoring its first FDA approval, AstraZeneca spinoff Viela is being bought out for $3 billion.

Horizon announced this morning that it is …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hori­zon nabs an­oth­er rare dis­ease pipeline for the port­fo­lio in $3B buy­out. And As­traZeneca — a fu­ture ri­val — is get­ting about $780M of that